top of page

MSF applauds Indian Patent Office’s rejection of J&J’s attempt to extend patent on lifesaving

Doctors Without Borders/Médecins Sans Frontières (MSF) applauds today’s news that the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly in India on the tuberculosis (TB) drug bedaquiline beyond when its primary patent expires in July. The rejection is a significant step toward increasing access to the lifesaving TB drug. Read more here.

13 views0 comments

Recent Posts

See All

Treat Action Group 2023 Pipeline Report

Their annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). View the full

Comments


bottom of page